Can Rigetti's Need for a Quantum Fab Reshape Its Long-Term Moat?

Rigetti said on its Q3 call that its 150mm Fremont fab will support development only through 2027 and is unlikely to deliver the >99.9% qubit fidelities needed for commercial systems, so management is pursuing partnerships with superconducting foundries, participation in U.S. government quantum manufacturing programs, or building a modern 200–300mm fab — actions that could materially improve process control, yields and economics and serve as a competitive differentiator if executed. Peer developments include Quantum Computing Inc. delivering its first commercial entangled-photon source and scaling production at its Tempe photonic foundry, and D-Wave moving its Advantage2 annealer (now >4,400 qubits) to full commercial availability via its Leap cloud and expanding hybrid quantum-classical offerings. Market context: RGTI is up 84.9% YTD, trades at a price-to-book of ~24.7, carries a Zacks Rank #3 (Hold) and faces analyst estimates that imply a large (~88.9%) decline in 2025 earnings, highlighting upside from technology milestones but significant near-term execution and profitability risk.

Analysis

Rigetti disclosed on its Q3 call that its 150mm Fremont fabrication line can support development only through 2027 but is unlikely to achieve the >99.9% qubit fidelities required for commercial-grade systems; management is pursuing three explicit paths—partnering with superconducting foundries, seeking participation in U.S. government quantum manufacturing initiatives, or building a modern 200–300mm fab with advanced tooling and automation. Management frames a future fab not as an open risk but as a potential competitive differentiator that would improve process control, qubit consistency, yields and long-term economics if executed successfully.

Market signals show a bifurcated picture: RGTI shares have risen 84.9% year-to-date yet trade at a price-to-book of ~24.7 and carry a Zacks Rank #3 (Hold), while the Zacks 2025 consensus implies an 88.9% decline in earnings versus the prior year, underscoring valuation and near-term profitability disconnects relative to technical milestones. Competitive context reinforces urgency—Quantum Computing Inc. has delivered a commercial entangled-photon source and is scaling its Tempe photonic foundry, and D-Wave has moved its Advantage2 annealer (>4,400 qubits) to full commercial availability via Leap across 40+ countries.

The core investment tension is execution and financing risk versus strategic upside from on-shore manufacturing control: partnerships or government funding would materially de-risk capital intensity and timeline, while a self-funded 200–300mm fab would require clear capex, timeline and yield metrics to justify current valuation. Investors should therefore treat company announcements about partnerships, grants, or detailed capex plans as primary catalysts and view fidelity and yield progress as leading indicators of derisking.

Key Decisions for Investors

• Monitor near-term announcements for a confirmed foundry partnership, government funding award, or a detailed 200–300mm fab capex and timeline, as any of these materially change dilution and execution risk
• Given RGTI's 84.9% YTD gain, elevated P/B (~24.7) and an 88.9% implied drop in 2025 earnings, consider trimming or refraining from adding to positions until the company provides concrete funding/execution clarity
• Evaluate selective exposure to peers QUBT and QBTS for nearer-term commercialization upside—QUBT's first commercial entangled-photon delivery and Tempe foundry scale, and QBTS's Advantage2 commercial availability and global Leap access are tangible revenue catalysts
• If maintaining a long-term stance on RGTI, use event-driven triggers (confirmed partnership or government program participation, published yield/fidelity metrics, or a detailed capex/dilution plan) before materially increasing exposure